Contineum Therapeutics, Inc. Operating Lease, Expense
Contineum Therapeutics, Inc. (CTNM) reported Operating Lease, Expense of $700.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-07-30
- Contineum Therapeutics, Inc. operating lease, expense for the quarter ending 2026-06-30 was $700.00K, a 75.00% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, expense for the quarter ending 2026-03-31 was $500.00K, a 25.00% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, expense for the quarter ending 2025-12-31 was $500.00K, a 150.00% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, expense for the quarter ending 2025-09-30 was $400.00K, a 33.33% increase year-over-year.
- Contineum Therapeutics, Inc. operating lease, expense for fiscal 2025 was $1.70M, a 54.55% increase from fiscal 2024.
- Contineum Therapeutics, Inc. operating lease, expense for fiscal 2024 was $1.10M.
- Contineum Therapeutics, Inc. operating lease, expense for fiscal 2022 was $900.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-07-30 | $1.20M 10-Q · filed 2026-07-30 | $1.70M derived: sum of 3 quarters · filed 2026-07-30 | $2.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-05 | $1.00M derived: sum of 2 quarters · filed 2026-05-05 | $1.40M derived: sum of 3 quarters · filed 2026-05-05 | $1.80M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $900.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.30M derived: sum of 3 quarters · filed 2026-07-30 | $1.70M 10-K · filed 2026-03-05 |
| 2025-09-30 | $400.00K 10-Q · filed 2025-10-30 | $800.00K derived: sum of 2 quarters · filed 2026-07-30 | $1.20M 10-Q · filed 2025-10-30 | $1.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $400.00K 10-Q · filed 2026-07-30 | $800.00K 10-Q · filed 2026-07-30 | $1.00M derived: sum of 3 quarters · filed 2026-07-30 | $1.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-05 | $600.00K derived: sum of 2 quarters · filed 2026-05-05 | $900.00K derived: sum of 3 quarters · filed 2026-05-05 | $1.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $500.00K derived: sum of 2 quarters · filed 2026-03-05 | $800.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-10-30 | $600.00K derived: sum of 2 quarters · filed 2025-10-30 | $900.00K 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-05 | $600.00K 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-14 | |||
| 2022-12-31 | $900.00K 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |